Astel­las' AML drug wins over CHMP — strength­en­ing lead on Dai­ichi Sankyo

Less than a year af­ter scor­ing a fast FDA OK for its pi­o­neer­ing acute myeloid leukemia drug gilter­i­tinib, Astel­las has snapped up a pos­i­tive rec­om­men­da­tion from Eu­ro­pean reg­u­la­tors fol­low­ing an ac­cel­er­at­ed as­sess­ment.

The CHMP thumbs up widens the gap be­tween Astel­las and Dai­ichi Sankyo, which has run in­to a road­block at the FDA when try­ing to field its own FLT3 tar­get­ed ther­a­py af­ter be­ing green-light­ed in Japan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.